Healthy
Conditions
Keywords
polyphenols, vascular function, endothelial function, raspberry
Brief summary
Accumulating evidence from epidemiological and human intervention studies indicates that the cardiovascular health benefits of diets rich in fruits and vegetables are (in part) related to their (poly)phenol content. Raspberries are rich in phenolic and polyphenolic compounds, in particular procyanidins, ellagitannins and anthocyanins, but also phenolic acids. At present, a small number of randomized controlled trials investigating the effects of berry (poly)phenols on validated surrogate markers of cardiovascular disease risk have shown promising results. However, to date, very few human studies have specifically investigated the effects of raspberry (poly)phenols on cardiovascular function in healthy subjects. Moreover, ellagitannin-derived metabolites are believed to persist for a long period of time in the blood and urine. Therefore, the investigators will investigate the presence of plasma and urinary raspberry-derived metabolites 24h post-consumption. To the investigators knowledge, the effects of red raspberry consumption on vascular function in humans have not been investigated before. This information is necessary for the planning of long-term studies aiming to assess the potential beneficial effects of raspberries,. Therefore, this study aims to investigate the potential role of red raspberry (poly)phenols in the modulation of vascular function by monitoring changes in vascular function together with the major (poly)phenol derivatives/metabolites in plasma.
Interventions
DIETARY_SUPPLEMENT400 g frozen raspberries
1x daily intake of 600 mL red raspberry beverage
DIETARY_SUPPLEMENT200 g frozen raspberries
1x daily intake of 600 mL red raspberry beverage
DIETARY_SUPPLEMENTPlacebo
1x daily intake of 600 mL raspberry deprived supplement
Sponsors
Heinrich-Heine University, Duesseldorf
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
MALE
Age
18 Years to 40 Years
Healthy volunteers
Yes
Inclusion criteria
* healthy male subjects (no clinical signs or symptoms of cardiovascular disease)
Exclusion criteria
* Cardiovascular disease * acute inflammation * cardiac arrhythmia * renal failure * heart failure (NYHA II-IV) * diabetes mellitus * C - reactive protein \> 05 mg/dL * malignant disease * raspberry allergy/intolerance * hypotension (≤100 / 60 mm Hg)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change from baseline to 2 hour and 24 hour in Endothelial function | Baseline, 2 hour and 24 hour | measured by flow mediated dilation (FMD) on baseline at 2 and 24 hour postconsumption |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change from baseline to 2 hour and 24 hour in Pulse wave velocity | Baseline, 2 hour and 24 hour | measured by sphygmomanometer SphygmoCor on baseline at 2 and 24 hours postconsumption |
| Change from baseline to 2 hour and 24 hour in Central blood pressure | Baseline, 2 hour and 24 hour | measured by sphygmomanometer SphygmoCor on baseline at 2 and 24 hours postconsumption |
| Peripheral blood pressure | Baseline, 2 h and 24 h | measured by automatic sphygmomanometer on baseline at 2 and 24 hours postconsumption |
| Change from baseline to 2 hour and 24 hour in Heart rate | Baseline, 2 hour and 24 hour | measured by SphygmoCor on baseline at 2 and 24 hours postconsumption |
Other
| Measure | Time frame | Description |
|---|---|---|
| Change from baseline to 2 hour and 24 hour in Polyphenol metabolites in blood plasma | Baseline, 2 hour and 24 hour | measured by ultra-performance liquid chromatography/quadrupole-time-of-flight mass-spectrometry (UPLC-Q-TOF MS ) on baseline at 2 and 24 hours postconsumption |
| Change from baseline to 2 hour and 24 hour in Polyphenol metabolites in urine | Baseline, 2 hour and 24 hour | measured by ultra-performance liquid chromatography/quadrupole-time-of-flight mass-spectrometry (UPLC-Q-TOF MS ) on baseline at 2 and 24 hours postconsumption |
Countries
Germany
Outcome results
None listed